Updated Results on Modakafusp Alfa (TAK-573) Safety and Efficacy; Phase 1/2 Study of RRMM Patients

Jonathan L. Kaufman's research works

Comparative safety of high-efficacy disease-modifying therapies in

MODAKAFUSP ALFA (TAK-573), Dan Vogl, MD, MSCE

Talquetamab in Pts with Relapsed/Refractory Multiple Myeloma

Cancers, Free Full-Text

Should smoldering myeloma patients start treatment?

Discussing Modakafusp Alfa as a Potential Treatment in RRMM

PDF) Current Main Topics in Multiple Myeloma

Myeloma Clinical Trials

Immunocytokine Therapy International Myeloma Foundation

Actor and Artist Ice-T Raises Awareness of Myeloma